Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Ryukaikon Agrees on Mandatory Barcode Labeling by March 2021; March 2022 for Exceptions
The health ministry’s “Ryukaikon” council for the improvement of ethical drug distributions, agreed on April 15 to make standardized barcode labeling mandatory for shipping packages and sales packages of prescription drugs by the end of March 2021 as a basic…
To read the full story
Related Article
- Barcode Labeling Increasing in Anticipation of Mandatory Use in 2021: MHLW Survey
September 6, 2016
- MHLW Issues Notification on Partial Revision of Rules for New Barcode Labeling to Be Required from April 2021
September 6, 2016
- MHLW to Place 2-Year Grace Period on Mandatory Barcode Labeling by March 2021 for Companies with “Special Circumstances”
June 6, 2016
- Wholesalers Cited Urgent Deliveries as Major Concern: Ryukaikon
April 19, 2016
- Wholesalers’ Negative Primary Margins on Sales Level Off: Ryukaikon
April 18, 2016
- Drug Makers, Distributors Won’t Set Interim Targets for Mandatory Barcode Labeling, but Keep Tabs on Progress
March 25, 2016
- Drug Makers, Distributors Rolling Up Their Sleeves for Mandatory Barcode Labeling
February 26, 2016
REGULATORY
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
- Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
- Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
- Expert Calls for AMR Ecosystem to Boost Japan Antibiotic Innovation
June 25, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…